• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EMA now accepting Safe-BioPharma digital signatures on eSubmissions

EMA now accepting Safe-BioPharma digital signatures on eSubmissions

September 6, 2013
CenterWatch Staff

Beginning this month, SAFE-BioPharma digital signatures will be accepted by the European Medicines Agency (EMA).  

Acceptance of digital signatures is in line with EMA’s strategy for a “future electronic only workflow” between itself and the pharmaceutical industry by eliminating the need and cost associated with printing, sending and archiving paper documents. Electronic only workflows involving regulatory submissions will require use of E.U.-qualified digital signatures such as those based on the SAFE-BioPharma standard.

The agency is starting with digital signature-enabled PDF forms for scientific advice, orphan medicines, and pediatric submissions. 

In a related announcement underscoring the agency’s strategy to increase electronic-document-only exchanges with industry, EMA said it “will start to use digital signatures systematically in outgoing documents that currently require a legally binding signature.”

“EMA’s acceptance and use of digital signatures sends an important message to biopharmaceutical companies, many of which have digital signing capability as part of their existing use of SAFE-BioPharma digital identity credentials,” said Mollie Shields Uehling, president and chief executive officer, SAFE-BioPharma Association.

The SAFE-BioPharma standard was established by the pharmaceutical industry with the participation of the EMA and FDA to create and maintain an interoperable digital identity and signature standard that allows secure, trusted exchanges and legally-binding digital signatures. SAFE-BioPharma member companies have conducted several pilots with the EMA demonstrating that the SAFE-BioPharma standard meets E.U. electronic signature requirements and that the EMA can recognize and validate SAFE-BioPharma compliant signatures.

The E.U. definition of digital signatures is consistent with SAFE-BioPharma digital signatures. Specifically, each signature is:

  • uniquely linked to the signatory
  • capable of identifying the signatory
  • created using data that the signatory can use under his/her sole control with a high level of confidence
  • linked to the signed document in such a way that subsequent change in the document is detectable.

The EMA requires digital signatures on submissions be issued from Certification Authorities (CAs) under the authority of the national agencies on the E.U. trusted list.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing